Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biontech Se ADR
(NQ:
BNTX
)
110.48
+4.17 (+3.92%)
Streaming Delayed Price
Updated: 10:12 AM EST, Nov 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biontech Se ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
October 13, 2022
From
BioNTech SE
Via
GlobeNewswire
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
October 13, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
October 12, 2022
From
BioNTech SE
Via
GlobeNewswire
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
October 12, 2022
From
Pfizer Inc.
Via
Business Wire
Is Pfizer Stock Still Worth Buying After the Pandemic?
October 12, 2022
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations.
Via
MarketBeat
Exposures
COVID-19
BioNTech and Australia’s State of Victoria Form Strategic Partnership to Establish mRNA Research Center and Manufacturing Facility
October 06, 2022
From
BioNTech SE
Via
GlobeNewswire
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
September 26, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
September 12, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
September 01, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
August 31, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
August 26, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
August 22, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
August 23, 2022
From
Pfizer Inc.
Via
Business Wire
Is Moderna's Cheaper Valuation A Buying Signal?
July 28, 2022
Moderna is one of the least expensive companies in the S&P 500 in terms of valuation. In this article, we'll examine other aspects of the company.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
July 27, 2022
From
BioNTech SE
Via
GlobeNewswire
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
August 11, 2022
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by...
Via
FinancialNewsMedia
Exposures
COVID-19
Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
June 29, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
June 25, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
June 17, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
May 23, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
May 17, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age
April 14, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
March 29, 2022
From
Pfizer Inc.
Via
Business Wire
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
March 24, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2022 – USA News Group – Whenever a new COVID-19 variant emergences, health authorities have had limited options to fight...
Via
FinancialNewsMedia
Exposures
COVID-19
Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age
February 11, 2022
From
Pfizer Inc.
Via
Business Wire
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
January 19, 2022
Via
AB Newswire
Topics
Bonds
Stocks
Exposures
Debt Markets
US Equities
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
January 05, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
January 03, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply
December 20, 2021
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older
December 09, 2021
From
Pfizer Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.